The Effect of Rifaximin on Gut Flora and Staphylococcus Resistance
- 610 Downloads
Rifaximin is a non-absorbed antibiotic relative of rifampicin. The location of effect and staphylococcal resistance are two recent potential concerns with rifaximin. In this study we evaluate the location of effect of rifaximin as well as the development of staphylococcal rifampicin resistance.
Rats were divided into three groups. Group 1 gavaged for 10 days with PBS, group 2 gavaged with rifaximin for 10 days, and group 3 gavaged with rifaximin for 10 days and housed for 30 days. In each group, stool was collected daily for quantitative culture of Staphylococcus spp. and coliforms. After euthanasia luminal bacterial counts were determined at multiple gut locations by qPCR. Rifampicin susceptibility was tested on Staphylococcus pre and post rifaximin.
At baseline, rats had a median of 2.90 × 106 cfu/ml Staphylococcus spp. in stool. After 10 days of rifaximin, this dropped to 1.20 × 105 cfu/ml (P < 0.01). With coliform counts, rats had a median of 1.86 × 104 cfu/ml at baseline which dropped to 2.2 × 103 cfu/ml (P < 0.01) after rifaximin. After cessation of rifaximin, coliform counts recovered within 3 days. When examining the total bacterial counts by qPCR, rifaximin reduced small bowel bacterial levels, but not colon. This reduction was sustained for 30 days. No colonies of Staphylococcus became resistant and only one colony was intermediate. The mean inhibitory concentration for rifampicin was not different before and after rifaximin.
Staphylococcal spp. fail to demonstrate resistance to rifampicin after rifaximin. The transient reductions in stool coliform counts recover while rifaximin appears to produce durable reductions in duodenal bacteria.
KeywordsRifaximin Staphylococcus Coliforms
This investigator-initiated study was supported by a grant from Salix Pharmaceuticals. In addition, this work was further supported by a grant from the Beatrice and Samuel A. Seaver Foundation.
Conflict of interest
Cedars-Sinai has a licensing agreement with Salix Pharmaceuticals. In additions, Drs. Pimentel and Chang are consultants for Salix Pharmaceuticals.
- 1.Marchi E, Masigianni G, Montecci L, Burfani M, Cellai L. L/105, A new semisynthetic derivative of ryfamicin SV, synthesis and structure-activity relationship. Chemioterapia. 1983;2:38–50.Google Scholar
- 12.DeLeo C, Dftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res. 1986;12:979–981.Google Scholar
- 13.Marchese A, Alerno A, Pesce A, Debbia EA, Schito GC. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy. 2000;46:253–266.PubMedCrossRefGoogle Scholar
- 19.Fera G, Agostinacchio F, Nigro M, et al. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res. 1993;4:57–66.Google Scholar
- 32.William DL, Spring L, Collins L, et al. Contribution of rpo B mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrb Agents Chemother. 1998;42:1985–1987.Google Scholar